8–9 June 2011 The 12th Annual Drug Discovery Leaders Summit 2011
12th ANNUAL DRUG DISCOVERy Leaders Summit
The Pharmaceutical industry is experiencing declining productivity and success rates. To stay competitive companies are both increasing collaborations and re-evaluating their drug discovery strategies in order to reduce attrition rates at later stages. Various research and decision making tools such as enabling technologies, biomarkers, and drug design are being enabled at different stages of the discovery process in order to revitalise efficiency and yield. Linking data produced during development stages back into discovery to produce translational and personlised medicine is also being utilised to bridge the gap between discovery and development.
The 12th Annual Drug Discovery Leaders Summit 2011 presented by Oxford Global Conferences provides a first class educational and networking opportunity for over 200 attendees to gain knowledge and insights into the entire Drug Discovery marketplace. Over 2 days, the comprehensive and scientific conference programme will feature key note addresses, case study presentations, panel and roundtable discussions of over 60 senior level industry speakers from leading pharmaceutical, biotechnology organisations as well as academia covering the following hot topics:
R&D STRATEGIES & BUSINESS MODELS– Challenges and strategies to enhance productivity in drug discovery such as open innovation, innovative collaboration models, stratification population strategies, addressing undruggable targets, early alliances & risk sharing portfolios and the assessment of drug discovery in a changing world.
MEDICINAL CHEMISTRY / DRUG DESIGN – DNA Encoded libraries, fragment based design, outsourcing, knowledge based drug design, natural compounds and analysis into how biophysical methods support drug disocvery.
BIOLOGICS – Strategies to integrate biologics into classical R&D models, presentations focused on the expansion into peptides, stapled peptides, soluble T cell receptors and the resurgence in antisense drugs.
ENABLING TECHNOLOGIES– Analysis of different technologies and their potential to benefit drug discovery such as antibodies, epigenetics, siRNA, RNAi, MicroRNA and constructing signalling pathways.
BIOINFORMATICS & DATA MANAGEMENT – Applications of Bioinformatics in discovery, focusing on uses of systems biology to find new targets, making models to make data more relevant to man and knowledge management tools.
SCREENING TECHNIQUES & ASSAY DEVELOPMENT – Improving value from HTS, potential of novel screening technologies, label free, disruptive technologies, potential of pluripotent stems cells Plus IMI Open Pharmacological Space Project.